A Michael J. Fox Foundation (MJFF) research fellow is leading a study into the role of social determinants in medical mistrust and the lack of clinical trial participation by people with diseases such as Parkinson’s who belong to racial, ethnic and social minority groups. Paris Adkins-Jackson’s study, titled “…
News
Clene Nanomedicine‘s investigational oral Parkinson’s treatment, CNM-Au8, safely and significantly increased energy metabolism in the brains of patients taking part in the Phase 2 REPAIR clinical trials, top-line results show. Greater energy metabolism is expected to lower oxidative stress in the brain, making more energy available to protect and…
Researchers with IBM and the Michael J. Fox Foundation developed a computational model that may help physicians better understand how Parkinson’s disease will progress among individuals. In their study, the algorithm — based on a branch of computer science called machine learning — identified groups of Parkinson’s symptoms and…
BiomeBank is launching a trial in Australia to test whether its fecal microbiota transplantation therapy, which works to replenish gut bacteria, is a safe, tolerable and effective treatment of Parkinson’s disease symptoms, such as constipation. The trial is being conducted in collaboration with the Royal Adelaide and Queen Elizabeth hospitals…
Farnesol, a natural compound of some herbs and fruits in commercial use, was seen to protect nerve cells in the brain and possibly restore some of these cells to health in multiple mouse models of Parkinson’s disease. Specifically, the compound prevented the loss of dopamine-producing neurons — nerve cells…
Opportunistic pathogens — microorganisms that live in us all,  but under specific circumstances can cause diseases like pneumonia — are more abundant in the mouths of people with Parkinson’s disease than healthy individuals, a study reported. This finding suggests that changes in oral bacteria in patients are related to disease…
Six microRNAs may serve as biomarkers of Parkinson’s disease progression and early diagnosis, a recent study suggests. That study, “Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease,” was published in the journal Translational Neurodegeneration. MicroRNAs (miRNAs)…
NRG Therapeutics has been awarded a $500,000 grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of its potential disease-modifying therapy for Parkinson’s. That funding will go toward investigating how small molecules, developed by NRG, inhibit the opening of mitochondrial pores, known…
It’s been a long, evolutionary road for The Michael J. Fox Foundation’s (MJFF) annual Tour de Fox fundraiser, which kicks off virtually this year on Aug. 28. The worldwide cycling event invites riders of all ages and abilities to put on helmets, check bike tire pressure, and take…
Head trauma causing a person to black out, and lead exposure — even through hobbies — may more than double a person’s risk of developing Parkinson’s disease, according to a study of people in the New England area. Having a close relative with this disease was also identified as…
Recent Posts
- Environmental factors may impact Parkinson’s disease risk: Dutch study
- Finding solutions for REM sleep behavior disorder with Parkinson’s
- The benefits of pets for those of us with Parkinson’s disease
- Sometimes being a Parkinson’s caregiver means just standing by
- Tips from an expert for traveling with Parkinson’s disease, part 1